Reading list
The record study supplies the opening problem. The drug papers address a narrower clinical question.
Care records and diagnosis
The primary-care observational study reports the management gap across female sexual dysfunction and erectile dysfunction. It supplies no trial evidence for closing that gap with bremelanotide.
The diagnostic review, the baseline-activity analysis and the expert round-table discussion address different disputes around low desire. The baseline paper's title contains language I question in the diagnosis essay.
Bremelanotide results
The randomized RECONNECT report and its open-label extension offer different kinds of follow-up. The regulatory critique challenges the clinical benefit; the pharmacotherapy review discusses limited efficacy and adverse effects.
The medical-treatment review specifies the premenopausal generalized acquired HSDD indication. The prescribing information is the source for the cardiovascular contraindications described here.
- Gap in Sexual Dysfunction Management Between Male and Female Patients Seen in Primary Care: An Observational Study. ↗
- Understanding Hypoactive Sexual Desire Disorder (HSDD) in Women: Etiology, Diagnosis, and Treatment. ↗
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials ↗
- Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. ↗
- Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women. ↗
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder ↗
- Bremelanotide Injection — US Prescribing Information (DailyMed/FDA) ↗
- Quantification of "Mercy Sex" in Heterosexual Women. ↗
- What Women Want? The State of the Art regarding the Treatment of Young Women with Hypoactive Sexual Desire Disorder. ↗
- Medical Treatment of Female Sexual Dysfunction. ↗